Hydroxymethylnitrofurazone lymphatic uptake with nanostructured lipid carrier after oral administration in rats

Nenhuma Miniatura disponível
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2024
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
FUTURE MEDICINE LTD
Autores
SOUZA, Aline de
SCARIM, Caue Benito
BARBOSA JUNIOR, Fernando
ROCHA, Bruno Alves
CALIXTO, Leandro Augusto
ARAUJO, Gabriel Lima de Barros
LOBENBERG, Raimar
BOU-CHACRA, Nadia Araci
Citação
NANOMEDICINE, v.19, n.4, p.293-301, 2024
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Leishmaniasis, caused by the protozoan Leishmania sp., infects phagocyte cells present in lymphatic organs. This study demonstrates the influence of nanostructured lipid carrier-loaded hydroxymethylnitrofurazone (NLC-NFOH) on lymphatic uptake using a chylomicron-blocking flow model in rats. Method: Lymphatic uptake of NFOH was assessed 1 h after oral administration of dimethyl sulfoxide with NFOH or NLC-NFOH with and without cycloheximide pretreatment. Result: Dimethyl sulfoxide with NFOH and NLC-NFOH showed NFOH serum concentrations of 0.0316 and 0.0291 mu g/ml, respectively. After chylomicron blocking, NFOH was not detected. Conclusion: Despite log P below 5, NFOH was successfully taken up by the lymphatic system. Long-chain fatty acids and particle size might be main factors in these findings. NLC-NFOH is a promising and convenient platform for treating leishmaniasis via oral administration.
Palavras-chave
chylomicrons, cycloheximide, hydroxymethylnitrofurazone, lymphatic system, nanostructured lipid carrier
URI
https://observatorio.fm.usp.br/handle/OPI/58893
Referências
  1. BOREN J, 1994, J BIOL CHEM, V269, P25879
  2. Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748
  3. Chaudhary S, 2015, INT J PHARMACEUT, V485, P108, DOI 10.1016/j.ijpharm.2015.02.070
  4. Chaudhary S, 2014, J DRUG TARGET, V22, P871, DOI 10.3109/1061186X.2014.950664
  5. Chavda H.V., 2010, Syst. Rev. Pharm, V1, P62
  6. Chung MC, 2003, BIOORGAN MED CHEM, V11, P4779, DOI 10.1016/j.bmc.2003.07.004
  7. Dahan A, 2005, EUR J PHARM SCI, V24, P381, DOI 10.1016/j.ejps.2004.12.006
  8. Das S, 2017, INT J BIOL MACROMOL, V102, P996, DOI 10.1016/j.ijbiomac.2017.04.098
  9. de Souza A, 2023, CHEM AFR, V6, P837, DOI 10.1007/s42250-022-00547-6
  10. de Souza A, 2020, COLLOID SURFACE B, V193, DOI 10.1016/j.colsurfb.2020.111097
  11. Fan ZY, 2013, INT J PHARMACEUT, V445, P141, DOI 10.1016/j.ijpharm.2013.01.070
  12. Fu Q, 2013, INT J PHARMACEUT, V448, P290, DOI 10.1016/j.ijpharm.2013.01.065
  13. Herman T.F., 2023, First Pass Effect
  14. Jitta SR., 2022, AAPS PHARMSCITECH, V23, P116
  15. Jitta SR, 2024, DRUG DELIV TRANSL RE, V14, P116, DOI 10.1007/s13346-023-01386-9
  16. Kar N, 2017, EUR J PHARM SCI, V104, P196, DOI 10.1016/j.ejps.2017.03.046
  17. Khan AA, 2013, INT J NANOMED, V8, P2733, DOI 10.2147/IJN.S41521
  18. Khan S, 2016, EUR J PHARM BIOPHARM, V109, P149, DOI 10.1016/j.ejpb.2016.10.011
  19. Mennini N, 2016, INT J PHARMACEUT, V515, P684, DOI 10.1016/j.ijpharm.2016.11.013
  20. Monteiro LM, 2017, INT J ANTIMICROB AG, V50, P88, DOI 10.1016/j.ijantimicag.2017.01.033
  21. Monteiro LM, 2015, BRAZ J PHARM SCI, V51, P561, DOI 10.1590/S1984-82502015000300008
  22. Monteiro LM., 2017, BIO MED RES INT, V2017, P1
  23. Moore JE, 2018, ANNU REV FLUID MECH, V50, P459, DOI 10.1146/annurev-fluid-122316-045259
  24. Organizacao Panamericana da Saude-Organizacao Mundial da Saude, 2016, LEISHM INF EP AM
  25. Patel P, 2021, EUR J PHARM SCI, V159, DOI 10.1016/j.ejps.2021.105715
  26. Serafim EOP, 2013, ANTIMICROB AGENTS CH, V57, P6106, DOI 10.1128/AAC.02522-12
  27. Poonia N, 2016, FUTUR SCI OA, V2, DOI 10.4155/fsoa-2016-0030
  28. Saleem K, 2019, NANOMATERIALS-BASEL, V9, DOI 10.3390/nano9121749
  29. Shete H, 2013, INT J PHARMACEUT, V454, P584, DOI 10.1016/j.ijpharm.2013.03.036
  30. Trevaskis NL, 2015, NAT REV DRUG DISCOV, V14, P781, DOI 10.1038/nrd4608
  31. WHO, 2021, LEISHM INF
  32. Xu Q, 2019, PHARM DEV TECHNOL, V24, P1155, DOI 10.1080/10837450.2019.1646757
  33. Yousef M, 2021, J PHARM PHARM SCI, V24, P533, DOI 10.18433/jpps32222
  34. Zhang ZC, 2021, ACTA PHARM SIN B, V11, P2449, DOI 10.1016/j.apsb.2020.12.022
  35. Zhu QG, 2021, ACTA PHARM SIN B, V11, P2416, DOI 10.1016/j.apsb.2021.04.001

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP